Giulia Mearini
University of Hamburg
Publications 34
#1Jirko Kühnisch (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 14
#2C. Herbst (MDC: Max Delbrück Center for Molecular Medicine)
Last.Brenda GerullH-Index: 20
view all 0 authors...
#1Maksymilian Prondzynski (UHH: University of Hamburg)H-Index: 6
#2Giulia Mearini (UHH: University of Hamburg)H-Index: 16
Last.Lucie Carrier (UHH: University of Hamburg)H-Index: 43
view all 3 authors...
Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disease with an estimated prevalence of 1:200 caused by mutations in sarcomeric proteins. It is associated with hypertrophy of the left ventricle, increased interstitial fibrosis, and diastolic dysfunction for heterozygous mutation carriers. Carriers of double heterozygous, compound heterozygous, and homozygous mutations often display more severe forms of cardiomyopathies, ultimately leading to premature death. So far, there is no cura...
#1Nico KresinH-Index: 1
#2Sabrina StückerH-Index: 1
Last.Lucie CarrierH-Index: 43
view all 10 authors...
Background. Many forms of hypertrophic cardiomyopathy (HCM) show an increased myofilament Ca2+ sensitivity. This observation has been mainly made in HCM mouse models, myofilament systems, and cardiomyocytes. Studies of multicellular tissues from patients with different HCM-associated gene mutations are scarce. We investigated Ca2+ sensitivity in multicellular cardiac muscle strips of HCM patients. We furthermore evaluated the use of epigallocatechin-3-gallate (EGCg), a Ca2+ desensitizer. Methods...
#1Kaja BreckwoldtH-Index: 7
Last.Sandra LauferH-Index: 2
view all 22 authors...
This protocol describes how to generate defined embryoid bodies and subsequent standardized beating engineered heart tissue from human iPSCs using small molecules.
#1Maksymilian Prondzynski (UHH: University of Hamburg)H-Index: 6
#2Elisabeth Krämer (UHH: University of Hamburg)H-Index: 10
Last.HansenArne (UHH: University of Hamburg)H-Index: 23
view all 14 authors...
Gene therapy is a promising option for severe forms of genetic diseases. We previously provided evidence for the feasibility of trans -splicing, exon skipping, and gene replacement in a mouse model of hypertrophic cardiomyopathy (HCM) carrying a mutation in MYBPC3 , encoding cardiac myosin-binding protein C (cMyBP-C). Here we used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from an HCM patient carrying a heterozygous c.1358-1359insC MYBPC3 mutation and from a healthy d...